The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 359:1068-1070 September 4, 2008 Number 10
NextNext

Aliskiren Combined with Losartan in Diabetes and Nephropathy

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Parving, H.-H.
-PubMed Citation
To the Editor: In the report on the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) study by Parving et al. (June 5 issue),1 there is convincing evidence that aliskiren, in addition to losartan, has a significant antiproteinuric effect, which supports the potential therapeutic role of a renin inhibitor in diabetic nephropathy. However, the authors do not indicate specifically the type of calcium-channel blocker the patients were concomitantly taking. Non-dihydropyridine calcium-channel blockers, such as diltiazem, have been shown to have antiproteinuric and renoprotective properties.2 Since more than 50% of the patients were taking a calcium-channel blocker, this may have . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.